Read the Drug Patent Clock Before the Market Does: A step-by-step technical guide to forecasting pharmaceutical drug patent expiry for IP teams, R&D strategists, and institutional investors
The drug patent clock is ticking—most IP teams only look at it after it’s already run out.
In pharma, timing isn’t just a legal concept. It’s a commercial weapon. Yet too many IP, R&D, and investment teams treat patent expiry like a static date on …
